Cabaletta Bio, Inc. (CABA)
CABANASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$1.45
-0.0487 (-3.25%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.45 +0.09%
- Market cap
- $312.79m
- P/E
- –
- EPS, last 4 quarters
- $-1.41
- Dividend yield
- –
- Day range
- $1.41 to $1.53
- 52-week range
- $1.18 to $4.23
- Average volume
- 5.50m
- Previous close
- $1.50
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $14.33, +887.4% from here
Earnings
next estimate $-0.2900Next report
Dec 2025
+11.1%
Mar 2026
+4.9%
Jun 2026
+8.1%
Sep 2026
+15.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$46.59m | -$42.61m | -$44.30m | -$52.02m |
| Net income | -$44.87m | -$41.92m | -$43.52m | -$51.02m |
News
8 latest- Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026Fintel · 1 day ago
- Cabaletta Bio Reports Positive Phase 1/2 Data For Rese-cel In Autoimmune Diseases; Stock Up RTTNews · 1 day ago
- Cabaletta Bio, Inc. Reports Third Quarter 2026 Financial Results and $299.4 million Cash PositionFintel · 5 days ago
- Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?Zacks · May 20, 2026
- Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should KnowZacks · Mar 6, 2026
- Are Medical Stocks Lagging Biodesix (BDSX) This Year?Zacks · Mar 3, 2026
- Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?Zacks · Feb 12, 2026
- What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?Zacks · Jan 30, 2026
The company
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta's lead product candidate, resecabtagene autoleucel (rese-cel), is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the REstoring SElf-Tolerance (RESET) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology, and dermatology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- cabalettabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.